Insulet (PODD) Stock Forecast & Price Target

Compare

976 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PODD Analyst Ratings

Strong Buy

17 Buy

1 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Insulet

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PODD Stock 12 Month Forecast

Average Price Target

$381.12

▲(29.54% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $381.12 with a high forecast of $432.00 and a low forecast of $316.00. The average price target represents a 29.54% change from the last price of $294.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"249":"$249","295":"$295","341":"$341","387":"$387","433":"$433"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$432.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":381.12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$381.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":316,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$316.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[249,295,341,387,433],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,310.83,320.15076923076924,329.47153846153844,338.7923076923077,348.1130769230769,357.43384615384616,366.75461538461536,376.0753846153846,385.3961538461538,394.7169230769231,404.0376923076923,413.35846153846154,422.6792307692308,{"y":432,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,310.83,316.23692307692306,321.64384615384614,327.0507692307692,332.4576923076923,337.8646153846154,343.27153846153846,348.67846153846153,354.0853846153846,359.4923076923077,364.89923076923077,370.30615384615385,375.7130769230769,{"y":381.12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,310.83,311.2276923076923,311.6253846153846,312.0230769230769,312.4207692307692,312.8184615384615,313.2161538461538,313.61384615384617,314.01153846153846,314.40923076923076,314.80692307692306,315.2046153846154,315.6023076923077,{"y":316,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":266.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":261.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":344.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":310.83,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$432.00

Average Price Target$381.12

Lowest Price Target$316.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Josh Jennings

TD Cowen

$379

Buy

28.82%

Upside

Reiterated

12/04/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (NASDAQ: BIOA) and Insulet (NASDAQ: PODD)We reiterate our Buy rating and $379 price target on PODD shares.

Patrick Wood

Morgan Stanley

$370

Buy

25.76%

Upside

Reiterated

12/04/25

Morgan Stanley Keeps Their Buy Rating on Insulet (PODD)

Danielle Antalffy

UBS

$400

Buy

35.96%

Upside

Reiterated

11/23/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (NASDAQ: PODD), Astrana Health (NASDAQ: ASTH) and Bristol-Myers Squibb (NYSE: BMY)

Richard Newitter

Truist Financial

$390→$412

Buy

40.04%

Upside

Reiterated

11/21/25

Insulet (PODD) Gets a Buy from Truist Financial

Matthew Taylor

Jefferies

$400

Buy

35.96%

Upside

Reiterated

11/21/25

Jefferies Sticks to Their Buy Rating for Insulet (PODD)

Matt Miksic

Barclays

$301→$316

Hold

7.41%

Upside

Reiterated

11/21/25

Insulet (PODD) Gets a Hold from Barclays

William Plovanic

Canaccord Genuity

$428→$432

Buy

46.84%

Upside

Reiterated

11/21/25

Insulet price target raised to $432 from $428 at CanaccordInsulet price target raised to $432 from $428 at Canaccord

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

11/21/25

Insulet's Promising Growth Potential: A Buy Rating Despite Market Skepticism

Marie Thibault

BTIG

$370→$380

Buy

29.16%

Upside

Reiterated

11/21/25

Insulet's Ambitious Growth Targets and Strategic Initiatives Reinforce Buy Rating with Revised Price Target of $380

Joanne Wuensch

Citi

$380

Buy

29.16%

Upside

Assigned

11/20/25

Insulet's Strong Market Position and Growth Prospects Justify Buy RatingWe think that some investors look at the Insulet TAM as largely penetrated; we think this is the wrong way to view it, and management underscored an opportunity to double the TAM to 17M. Starting with the current 8M TAM, it adds 4M OUS T2 patients, plus 3M U.S. in Asia. Currently, AID penetration lags CGM penetration. For example, in the U.S., AID penetration is 40%, lagging CGM’s 70% rate. OUS is even broader, with only one in four on AID therapy where CGM penetration is 65%. And this is just 2 utilization just getting started in the 12B WW T2 market that is less than 5% penetrated (with management looking to double the penetration rate over the LRP); see Figure 1.

Travis Steed

Bank of America Securities

$360

Buy

22.37%

Upside

Reiterated

11/20/25

Insulet's Strategic Growth and Innovation Drive 'Buy' Rating with $360 Price Target

Shagun Singh Chadha

RBC Capital

$370→$380

Buy

29.16%

Upside

Reiterated

11/20/25

RBC Capital Remains a Buy on Insulet (PODD)

Jonathan Block

Stifel Nicolaus

$370

Buy

25.76%

Upside

Reiterated

11/07/25

Stifel Nicolaus Sticks to Its Buy Rating for Insulet (PODD)

Larry Biegelsen

Wells Fargo

$350→$360

Buy

22.37%

Upside

Reiterated

11/07/25

Insulet price target raised to $360 from $350 at Wells FargoInsulet price target raised to $360 from $350 at Wells Fargo

Lee Hambright

Bernstein

$400→$410

Buy

39.36%

Upside

Assigned

11/07/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Alnylam Pharma (NASDAQ: ALNY) and Insulet (NASDAQ: PODD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Josh Jennings

TD Cowen

$379

Buy

28.82%

Upside

Reiterated

12/04/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (NASDAQ: BIOA) and Insulet (NASDAQ: PODD)We reiterate our Buy rating and $379 price target on PODD shares.

Patrick Wood

Morgan Stanley

$370

Buy

25.76%

Upside

Reiterated

12/04/25

Morgan Stanley Keeps Their Buy Rating on Insulet (PODD)

Danielle Antalffy

UBS

$400

Buy

35.96%

Upside

Reiterated

11/23/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (NASDAQ: PODD), Astrana Health (NASDAQ: ASTH) and Bristol-Myers Squibb (NYSE: BMY)

Richard Newitter

Truist Financial

$390→$412

Buy

40.04%

Upside

Reiterated

11/21/25

Insulet (PODD) Gets a Buy from Truist Financial

Matthew Taylor

Jefferies

$400

Buy

35.96%

Upside

Reiterated

11/21/25

Jefferies Sticks to Their Buy Rating for Insulet (PODD)

Matt Miksic

Barclays

$301→$316

Hold

7.41%

Upside

Reiterated

11/21/25

Insulet (PODD) Gets a Hold from Barclays

William Plovanic

Canaccord Genuity

$428→$432

Buy

46.84%

Upside

Reiterated

11/21/25

Insulet price target raised to $432 from $428 at CanaccordInsulet price target raised to $432 from $428 at Canaccord

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

11/21/25

Insulet's Promising Growth Potential: A Buy Rating Despite Market Skepticism

Marie Thibault

BTIG

$370→$380

Buy

29.16%

Upside

Reiterated

11/21/25

Insulet's Ambitious Growth Targets and Strategic Initiatives Reinforce Buy Rating with Revised Price Target of $380

Joanne Wuensch

Citi

$380

Buy

29.16%

Upside

Assigned

11/20/25

Travis Steed

Bank of America Securities

$360

Buy

22.37%

Upside

Reiterated

11/20/25

Insulet's Strategic Growth and Innovation Drive 'Buy' Rating with $360 Price Target

Shagun Singh Chadha

RBC Capital

$370→$380

Buy

29.16%

Upside

Reiterated

11/20/25

RBC Capital Remains a Buy on Insulet (PODD)

Jonathan Block

Stifel Nicolaus

$370

Buy

25.76%

Upside

Reiterated

11/07/25

Stifel Nicolaus Sticks to Its Buy Rating for Insulet (PODD)

Larry Biegelsen

Wells Fargo

$350→$360

Buy

22.37%

Upside

Reiterated

11/07/25

Insulet price target raised to $360 from $350 at Wells FargoInsulet price target raised to $360 from $350 at Wells Fargo

Lee Hambright

Bernstein

$400→$410

Buy

39.36%

Upside

Assigned

11/07/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Alnylam Pharma (NASDAQ: ALNY) and Insulet (NASDAQ: PODD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insulet

1 Month

xxx

Success Rate

14/22 ratings generated profit

Average Return

+3.69%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +3.69% per trade.

3 Months

xxx

Success Rate

16/18 ratings generated profit

Average Return

+13.12%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +13.12% per trade.

1 Year

Matthew TaylorJefferies

Success Rate

15/18 ratings generated profit

Average Return

+29.97%

reiterated a buy rating 20 days ago

Copying Matthew Taylor's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +29.97% per trade.

2 Years

xxx

Success Rate

23/24 ratings generated profit

Average Return

+76.42%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.83% of your transactions generating a profit, with an average return of +76.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PODD Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PODD has received 34 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. PODD average Analyst price target in the past 3 months is 381.12.

Each month's total comprises the sum of three months' worth of ratings.

PODD Financial Forecast

PODD Earnings Forecast

Next quarter’s earnings estimate for PODD is $1.46 with a range of $1.32 to $1.86. The previous quarter’s EPS was $1.24. PODD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PODD has Performed in-line its overall industry.

PODD Sales Forecast

Next quarter’s sales forecast for PODD is $768.47M with a range of $755.60M to $778.00M. The previous quarter’s sales results were $706.30M. PODD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PODD has Performed in-line its overall industry.

PODD Stock Forecast FAQ

What is PODD’s average 12-month price target, according to analysts?

Based on analyst ratings, Insulet’s 12-month average price target is 381.12.

What is PODD’s upside potential, based on the analysts’ average price target?

Insulet has 29.54% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PODD a Buy, Sell or Hold?

Insulet has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.

What is Insulet’s price target?

The average price target for Insulet is 381.12. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $432.00 ,the lowest forecast is $316.00. The average price target represents 29.54% Increase from the current price of $294.2.

What do analysts say about Insulet?

Insulet’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of PODD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Insulet (PODD) Stock Forecast & Price Target

PODD Analyst Ratings

PODD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insulet

PODD Analyst Recommendation Trends

PODD Financial Forecast

PODD Earnings Forecast

PODD Sales Forecast

PODD Stock Forecast FAQ

Detailed List of Analyst Forecasts